Global drugmaker AbbVie will invest $380 million to build two new manufacturing facilities at its North Chicago campus, the company said on Monday.The plants will make active pharmaceutical ingredients for AbbVie’s obesity and neuroscience medications. They will create at least 300 full-time jobs, including roles for engineers, scientists, manufacturing operators and lab technicians.Construction will start this spring, with the facilities opening in 2029.“This milestone demonstrates further progress against AbbVie’s $100 billion commitment to U.S. research and development, and capital investments over the next decade,” AbbVie CEO Robert Michael said in a news release.The news comes after AbbVie broke ground in September on another $195 million manufacturing facility in North Chicago, where it’s headquartered. It will create about 50 full-time jobs when it opens in 2027. The plant will manufacture neuroscience, immunology and oncology products.“AbbVie’s significant investment fortifies Illinois’ position as a global biomanufacturing leader while creating hundreds of new jobs,” Gov. JB Pritzker said in a Monday news release.In January, AbbVie announced a voluntary agreement with President Donald Trump’s administration to invest $100 billion in U.S.-based research and development and capital investments, including manufacturing sites, over the next decade, according to a news release.AbbVie will also offer its medicines through TrumpRx, the government website launched this month.The drugmaker’s agreement includes the Trump administration giving AbbVie exemption from tariffs and future price mandates, according to a news release.Through Illinois’ Economic Growth Plan, Pritzker has underscored expanding life sciences and advanced manufacturing to strengthen the state’s economy. Other key growth industries in…
Want more insights? Join Grow With Caliber - our career elevating newsletter and get our take on the future of work delivered weekly.
